194 related articles for article (PubMed ID: 32580297)
21. Identification of antitumor lignans from the seeds of morning glory (Pharbitis nil).
Kim KH; Woo KW; Moon E; Choi SU; Kim SY; Choi SZ; Son MW; Lee KR
J Agric Food Chem; 2014 Aug; 62(31):7746-52. PubMed ID: 25020073
[TBL] [Abstract][Full Text] [Related]
22. Antibacterial Activity of Pharbitin, Isolated from the Seeds of
Nguyen HT; Yu NH; Park AR; Park HW; Kim IS; Kim JC
J Microbiol Biotechnol; 2017 Oct; 27(10):1763-1772. PubMed ID: 28851207
[TBL] [Abstract][Full Text] [Related]
23. The current understanding on the impact of KRAS on colorectal cancer.
Meng M; Zhong K; Jiang T; Liu Z; Kwan HY; Su T
Biomed Pharmacother; 2021 Aug; 140():111717. PubMed ID: 34044280
[TBL] [Abstract][Full Text] [Related]
24. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
[TBL] [Abstract][Full Text] [Related]
25. Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer.
Toda K; Nishikawa G; Iwamoto M; Itatani Y; Takahashi R; Sakai Y; Kawada K
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28749408
[TBL] [Abstract][Full Text] [Related]
26. Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer.
Bahrami A; Hassanian SM; ShahidSales S; Farjami Z; Hasanzadeh M; Anvari K; Aledavood A; Maftouh M; Ferns GA; Khazaei M; Avan A
J Cell Physiol; 2018 Mar; 233(3):2058-2066. PubMed ID: 28262927
[TBL] [Abstract][Full Text] [Related]
27. Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer.
Belli S; Pesapane A; Servetto A; Esposito D; Napolitano F; Ascione CM; Allotta A; Zambrano N; Marino FZ; Franco R; Troiani T; Formisano L; Bianco R
Br J Cancer; 2023 Oct; 129(7):1071-1082. PubMed ID: 37568037
[TBL] [Abstract][Full Text] [Related]
28. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
[TBL] [Abstract][Full Text] [Related]
29. Phellinus linteus Grown on Germinated Brown Rice Increases Cetuximab Sensitivity of KRAS-Mutated Colon Cancer.
Park HJ; Park JB; Lee SJ; Song M
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28800074
[TBL] [Abstract][Full Text] [Related]
30. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
[TBL] [Abstract][Full Text] [Related]
31. Mediatory role of BLT2 in the proliferation of KRAS mutant colorectal cancer cells.
Park J; Jang JH; Kim JH
Biochim Biophys Acta Mol Cell Res; 2019 Mar; 1866(3):329-336. PubMed ID: 30553812
[TBL] [Abstract][Full Text] [Related]
32. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
Song Q; Sun X; Guo H; Yu Q
Oncotarget; 2017 Jan; 8(3):5003-5015. PubMed ID: 28002807
[TBL] [Abstract][Full Text] [Related]
33. Acylated glycosides of hydroxy fatty acid methyl esters generated from the crude resin glycoside (pharbitin) of seeds of Pharbitis nil by treatment with indium(III) chloride in methanol.
Ono M; Takigawa A; Mineno T; Yoshimitsu H; Nohara T; Ikeda T; Fukuda-Teramachi E; Noda N; Miyahara K
J Nat Prod; 2010 Nov; 73(11):1846-52. PubMed ID: 20939542
[TBL] [Abstract][Full Text] [Related]
34. Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review.
Bteich F; Mohammadi M; Li T; Bhat MA; Sofianidi A; Wei N; Kuang C
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569406
[TBL] [Abstract][Full Text] [Related]
35. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.
Sen M; Wang X; Hamdan FH; Rapp J; Eggert J; Kosinsky RL; Wegwitz F; Kutschat AP; Younesi FS; Gaedcke J; Grade M; Hessmann E; Papantonis A; Strӧbel P; Johnsen SA
Clin Epigenetics; 2019 Jun; 11(1):92. PubMed ID: 31217031
[TBL] [Abstract][Full Text] [Related]
36. Novel Polymethoxylated Chalcones as Potential Compounds Against KRAS-Mutant Colorectal Cancers.
Mahmoud A; Elkhalifa D; Alali F; Al Moustafa AE; Khalil A
Curr Pharm Des; 2020; 26(14):1622-1633. PubMed ID: 32026770
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
Pehserl AM; Ress AL; Stanzer S; Resel M; Karbiener M; Stadelmeyer E; Stiegelbauer V; Gerger A; Mayr C; Scheideler M; Hutterer GC; Bauernhofer T; Kiesslich T; Pichler M
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27916938
[TBL] [Abstract][Full Text] [Related]
38. Regulation of intestinal myofibroblasts by KRas-mutated colorectal cancer cells through heparin-binding epidermal growth factor-like growth factor.
Kawasaki H; Saotome T; Usui T; Ohama T; Sato K
Oncol Rep; 2017 May; 37(5):3128-3136. PubMed ID: 28339087
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway.
Conti A; Majorini MT; Elliott R; Ashworth A; Lord CJ; Cancelliere C; Bardelli A; Seneci P; Walczak H; Delia D; Lecis D
Oncotarget; 2015 May; 6(13):10994-1008. PubMed ID: 26028667
[TBL] [Abstract][Full Text] [Related]
40. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
Weng WH; Leung WH; Pang YJ; Hsu HH
Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
